Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Notes Payables (2016 - 2018)

Historic Notes Payables for Viking Therapeutics (VKTX) over the last 5 years, with Q1 2018 value amounting to $3.7 million.

  • Viking Therapeutics' Notes Payables changed N/A to $3.7 million in Q1 2018 from the same period last year, while for Mar 2018 it was $3.7 million, marking a year-over-year change of. This contributed to the annual value of $3.5 million for FY2017, which is 554.87% up from last year.
  • According to the latest figures from Q1 2018, Viking Therapeutics' Notes Payables is $3.7 million.
  • Over the past 5 years, Viking Therapeutics' Notes Payables peaked at $3.7 million during Q1 2018, and registered a low of $304274.0 during Q4 2014.
  • In the last 5 years, Viking Therapeutics' Notes Payables had a median value of $2.5 million in 2015 and averaged $2.4 million.
  • Its Notes Payables has fluctuated over the past 5 years, first skyrocketed by 72162.79% in 2015, then soared by 554.87% in 2017.
  • Viking Therapeutics' Notes Payables (Quarter) stood at $304274.0 in 2014, then surged by 721.63% to $2.5 million in 2015, then skyrocketed by 30.78% to $3.3 million in 2016, then grew by 5.55% to $3.5 million in 2017, then grew by 7.82% to $3.7 million in 2018.
  • Its Notes Payables stands at $3.7 million for Q1 2018, versus $3.5 million for Q4 2017 and $3.2 million for Q3 2017.